Ensuring access to COVID-19 vaccines for low- and middle-income economies
What is the Gavi COVAX AMC?
At the Global Vaccine Summit on June 4, Gavi launched the COVID-19 Vaccines Advance Market Commitment (COVAX AMC) as the first building block of the COVAX Facility. The Gavi COVAX AMC is the innovative financing instrument that will support the participation of 92 low- and middle-income economies in the COVAX Facility – enabling access to donor-funded doses of safe and effective COVID-19 vaccines. The AMC, combined with additional support for country readiness and delivery, will make sure the most vulnerable in all countries can be protected in the short term, regardless of income level.
Latest AMC news
The signed advance purchase agreement (APA) is for up to 500 million doses of the COVID-19 vaccine manufactured by Moderna. Supply via the agreement will take place from the second half of 2021 through 2022, with options in place to address the…
Today, to mark the first year of the creation of the Access to COVID-19 Tools (ACT) Accelerator, President Emmanuel Macron announced that France has begun sharing vaccine doses with COVAX, starting with a first batch of 105,600 doses – with 500,…
Over half a million doses of COVID-19 vaccines arrived in Angola in March, delivered through the COVAX initiative. VaccinesWork talked to some of the first beneficiaries.
Óscar Gil Pereira is one of Angola’s most celebrated filmmakers. Last year he became one of the 24,000 people in Angola to contract COVID-19. After beating the disease, he is now vaccinated and committed to celebrating the health worker heroes…
The pandemic has strained most countries’ health systems. Afghanistan has faced more hurdles than most.
COVAX has a critical role to play in ending the acute phase of the pandemic. The initiative could also be a model for how we address some of the most urgent development challenges of our time, from climate change to poverty reduction.
The delivery of vaccines has gone a long way to alleviating the fears and pressure on healthcare workers in Eswatini.
Millions of doses of COVID-19 vaccines are being delivered across the world, but what do we know about how long will immunity last?
The “One World Protected” Event, hosted today by the United States and Gavi, the Vaccine Alliance, launched a campaign to raise US$ 2 billion for the global fight against COVID-19.
The delivery of COVID-19 vaccines to Eswatini through COVAX means the elderly now have the chance to protect themselves against the disease. VaccinesWork visits a vaccination session in Lobamba.
The COVAX Facility has now delivered life-saving vaccines to over 100 economies since making its first international delivery to Ghana on February 24th.
The virtual event will bring together world leaders, the private sector, civil society, and key technical partners to galvanize resources and commitment to the Gavi COVAX Advance Market Commitment (AMC).
COVID-19 vaccination campaigns using COVAX-funded doses commenced today in Côte d’Ivoire and Ghana, the first global rollout.
This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
The World Health Organization has given the Oxford-AstraZeneca vaccine an Emergency Use Listing, passing an important milestone before the first delivery of COVAX vaccines worldwide.
Gavi’s CEO explains how the COVAX Advance Market Commitment mechanism will make COVID-19 vaccines available to lower-income countries.
The medical and moral imperative for equitable access to COVID-19 vaccines is why COVAX was created. Co-led by Gavi, the Vaccine Alliance, together with the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (…
The COVAX AMC Engagement Group, composed of Gavi COVAX AMC participants, donors, and other stakeholders, forms a key component of Facility governance.
The European Commission, France, Spain, The Republic of Korea and the Bill & Melinda Gates Foundation pledge US$ 360 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)
Never has the development of vaccines been so widely anticipated as for COVID-19, and arguably never has so much been at stake. Because without COVID-19 vaccines, we cannot bring this crisis to a swift end.
Japanese Government pledges US$ 130 million in funding to the Gavi COVAX Advance Market Commitment (AMC), bringing the total raised to roughly US$ 1.8 billion.
The United Kingdom, Canada, Germany, Italy and Sweden pledge approximately US$ 960 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)
The Gavi Board has approved the provision of US$ 150 million in initial funding to jumpstart support COVAX AMC-eligible countries’ readiness to deliver COVID-19 vaccines, in the form of planning, technical assistance and cold chain equipment
Collaboration among the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation will accelerate manufacturing and delivery of up to an additional 100 million doses of future vaccines, if proven to be…
The funding will support the Gavi COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations
New landmark collaboration between the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation to accelerate manufacturing and delivery of up to 100 million doses of future safe and effective COVID-…
Gavi Board agrees scope of COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations.
Global technology company TransferWise and a donor which asked to remain anonymous made significant financial commitments to Gavi’s Advance Market Commitment for COVID-19 Vaccines (Gavi COVAX AMC)
Gavi Board shows support for continued work on COVAX Facility: a global, coordinated mechanism designed to ensure rapid and equitable access to safe and efficacious COVID-19 vaccines to as broad a global population as possible
With more than 200 COVID-19 vaccines already in development, why do we need the Access to COVID-19 Tools Accelerator Vaccine Pillar, or COVAX Pillar?
Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC) launched at Global Vaccine Summit 2020 draws strong support, early commitments from global leaders.
COVAX AMC Engagement Group Co-Chairs
Karina Gould
Minister of International Development, Canada
Retno L.P. Marsudi
Minister for Foreign Affairs, Indonesia
Lia Tadesse
Minister of Health, Ethiopia
Accessing COVID-19 vaccines via the COVAX AMC
COVAX AMC application process
Countries eligible for the Gavi COVAX AMC are required to confirm participation in the COVAX Facility and complete a Vaccine Request in order to be allocated doses of COVID-19 vaccine.
In addition, all AMC participants are eligible to request support for cold chain equipment (CCE) and technical assistance (TA). Priority would be given to the Gavi-Eligible Countries.
A Vaccine Request is required for requests for CCE support to be considered, however this is not the case for TA support, which can be applied for before a Vaccine Request is submitted.
All relevant documents, including information on deadlines, can be found below.
| Cut off deadline for submission of revised applications | IRC meeting (indicative dates) |
|---|---|
| 12 February | 1-5 March |
| 9 March | 25 March-1 April |
| 2 April | 19-23 April |
| 29 April | 17-21 May |
| 27 May | 14-18 June |
For further information, Gavi-eligible countries should reach out to their Senior Country Manager. All other Participants should reach out to their focal point. If unsure of the appropriate contact point, questions can be directed to covaxproposals@gavi.org.
NOTE: Participants may request WHO and UNICEF country offices to provide assistance to complete submissions such as the Vaccine Request and request for support for CCE. Gavi has made funding available to WHO and UNICEF for this purpose.
COVAX AMC application documents
COVAX AMC - APPLICATION overview
An outline of the process that countries will be required to follow for COVAX Facility funding as well as elements to consider in requests.
Vaccine Request
COVAX AMC Eligible Economies should confirm participation in the AMC by submitting a completed and signed Vaccine Request – Part A, which should be submitted to covaxproposals@gavi.org, with a copy sent to the relevant Gavi Senior Country Manager (if applicable) or country focal point by 7 December 2020. To complete the submission Vaccine Request – Part B should be submitted to covaxproposals@gavi.org, with a copy sent to the relevant Gavi Senior Country Manager or focal point (whichever is applicable) by 8 January 2020.
Technical assistance
To prepare all countries for COVID-19 vaccine introduction, WHO, UNICEF, Gavi, and partners are working together at the global and regional levels to support the AMC economies in the planning and preparation for introducing the COVID-19 vaccine. All AMC 92 economies are eligible to request TA although priority will be given to Gavi-eligible countries.
Cold chain equipment support
The COVAX Facility is making available cold chain equipment (CCE) support to participating AMC 92 countries, although priority will be given to the 57 Gavi-eligible economies. Find below guidance on how to complete the application, descriptions of supported technologies and services and the necessary forms and templates to complete.
Key resources
Last updated: 21 Apr 2021